Eli Lilly and Company (NYSE:LLY) Shares Sold by Pennsylvania Capital Management Inc. ADV

Pennsylvania Capital Management Inc. ADV decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 1.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,185 shares of the company’s stock after selling 61 shares during the period. Eli Lilly and Company makes up approximately 1.3% of Pennsylvania Capital Management Inc. ADV’s investment portfolio, making the stock its 15th largest position. Pennsylvania Capital Management Inc. ADV’s holdings in Eli Lilly and Company were worth $3,456,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the fourth quarter worth about $43,000. Prudent Man Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $48,000. Highline Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 53.3% during the 1st quarter. Highline Wealth Partners LLC now owns 69 shares of the company’s stock worth $57,000 after buying an additional 24 shares during the last quarter. Capital A Wealth Management LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $63,000. Finally, Bellwether Advisors LLC acquired a new stake in Eli Lilly and Company during the fourth quarter worth $66,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on LLY shares. Wells Fargo & Company reissued an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Guggenheim reissued a “buy” rating and set a $936.00 price objective on shares of Eli Lilly and Company in a research report on Friday. UBS Group dropped their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target for the company. Finally, Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,011.79.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $770.16 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The firm has a fifty day moving average price of $780.81 and a 200 day moving average price of $800.36. The company has a market cap of $729.91 billion, a P/E ratio of 62.67, a PEG ratio of 1.11 and a beta of 0.41. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company’s revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.58 earnings per share. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.78%. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.